Gender-Specific Prognostic Impact of Treosulfan Levels in High-Dose Chemotherapy for Multiple Myeloma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Oct 16

PMID 39409984

Authors

Alexander D Heini

Karin Kammermann

Ulrike Bacher

Barbara Jeker

Michael Hayoz

Yolanda Aebi

Carlo R Largiader

Henning Nilius

Thomas Pabst

Affiliations

Soon will be listed here.

Abstract

Introduction: The growing body of evidence around sexual and gender dimorphism in medicine, particularly in oncology, has highlighted differences in treatment response, outcomes, and side effects between males and females. Differences in drug metabolism, distribution, and elimination, influenced by factors like body composition and enzyme expression, contribute to these variations.

Methods: We retrospectively analyzed data of 112 multiple myeloma (MM) patients treated with first-line high-dose chemotherapy (HDCT) with treosulfan and melphalan (TreoMel) followed by autologous stem cell transplantation (ASCT) at a single academic center between January 2020 and August 2022. We assessed response rate, progression-free survival (PFS), overall survival (OS), and toxicities in relation to gender and treosulfan exposure.

Results: Our analysis revealed significant gender-specific differences in treosulfan exposure. Females had higher peak levels (343.8 vs. 309.0 mg/L, = 0.0011) and area under the curve (AUC) (869.9 vs. 830.5 mg*h/L, = 0.0427) compared to males. Higher treosulfan exposure was associated with increased mortality in females but not in males. Females with treosulfan AUC > 900 mg*h/L had significantly shorter overall survival, while PFS was unaffected by treosulfan exposure.

Conclusion: Our study demonstrates that female patients undergoing TreoMel HDCT have higher treosulfan exposure than males and that females with higher levels are at increased risk for toxicity and adverse outcomes. These data suggest that higher treosulfan doses do not confer a benefit in terms of better outcomes for females. Therefore, exploring lower treosulfan doses for female MM patients undergoing TreoMel HDCT may be warranted to mitigate toxicity and improve outcomes.

References

Beelen D, Trenschel R, Casper J, Freund M, Hilger R, Scheulen M . Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 2004; 35(3):233-41. DOI: 10.1038/sj.bmt.1704784. View

Romanski M, Wachowiak J, Glowka F . Treosulfan Pharmacokinetics and its Variability in Pediatric and Adult Patients Undergoing Conditioning Prior to Hematopoietic Stem Cell Transplantation: Current State of the Art, In-Depth Analysis, and Perspectives. Clin Pharmacokinet. 2018; 57(10):1255-1265. PMC: 6132445. DOI: 10.1007/s40262-018-0647-4. View

Ngo L, Hee S, Lim L, Tao M, Quek R, Yap S . Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab. Leuk Lymphoma. 2008; 49(3):462-9. DOI: 10.1080/10428190701809156. View

Gillich C, Akhoundova D, Hayoz M, Aebi Y, Largiader C, Seipel K . Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma. Cancers (Basel). 2023; 15(10). PMC: 10216371. DOI: 10.3390/cancers15102699. View

Bird S, Cairns D, Menzies T, Boyd K, Davies F, Cook G . Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clin Lymphoma Myeloma Leuk. 2021; 21(10):667-675. PMC: 8528179. DOI: 10.1016/j.clml.2021.04.013. View

Unger J, Vaidya R, Albain K, LeBlanc M, Minasian L, Gotay C . Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. J Clin Oncol. 2022; 40(13):1474-1486. PMC: 9061143. DOI: 10.1200/JCO.21.02377. View

Ali M, Al Hadidi S . High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma. Transplant Cell Ther. 2022; 28(9):572-580. DOI: 10.1016/j.jtct.2022.06.013. View

Mueller F, Buchel B, Koberle D, Schurch S, Pfister B, Krahenbuhl S . Gender-specific elimination of continuous-infusional 5-fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study. Cancer Chemother Pharmacol. 2012; 71(2):361-70. DOI: 10.1007/s00280-012-2018-4. View

Gurevich E, Hayoz M, Aebi Y, Largiader C, Taleghani B, Bacher U . Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML. Cancers (Basel). 2022; 14(4). PMC: 8869805. DOI: 10.3390/cancers14041024. View

10.

Moreau P, Karamanesht I, Domnikova N, Kyselyova M, Vilchevska K, Doronin V . Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. Clin Pharmacokinet. 2012; 51(12):823-9. DOI: 10.1007/s40262-012-0010-0. View

11.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M . Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017; 376(14):1311-1320. PMC: 6201242. DOI: 10.1056/NEJMoa1611750. View

12.

Hunt C, Westerkam W, Stave G . Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992; 44(2):275-83. DOI: 10.1016/0006-2952(92)90010-g. View

13.

Horwitz S, OConnor O, Pro B, Trumper L, Iyer S, Advani R . The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2021; 33(3):288-298. PMC: 9447792. DOI: 10.1016/j.annonc.2021.12.002. View

14.

Dobbs N, Twelves C, Gillies H, James C, Harper P, Rubens R . Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol. 1995; 36(6):473-6. DOI: 10.1007/BF00685796. View

15.

Aycicek S, Akhoundova D, Bacher U, Hayoz M, Aebi Y, Largiader C . Determinants of Interpatient Variability in Treosulfan Pharmacokinetics in AML Patients Undergoing Autologous Stem Cell Transplantation. Int J Mol Sci. 2024; 25(15). PMC: 11311427. DOI: 10.3390/ijms25158215. View

16.

Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst H, Goldschmidt H, Rosinol L . Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015; 33(26):2863-9. PMC: 4846284. DOI: 10.1200/JCO.2015.61.2267. View

17.

Posch D, Rabitsch W, Wohlfarth P, Leiner M, Porpaczy E, Drach J . Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience. Oncology. 2017; 93(5):295-301. DOI: 10.1159/000478265. View

18.

Boyd K, Ross F, Chiecchio L, Dagrada G, Konn Z, Tapper W . Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2011; 20(8):1703-7. PMC: 4545514. DOI: 10.1158/1055-9965.EPI-11-0157. View

19.

Pai A, Mohanan E, Panetta J, Kulkarni U, Stallon Illangeswaran R, Balakrishnan B . Treosulfan Exposure Predicts Thalassemia-Free Survival in Patients with Beta Thalassemia Major Undergoing Allogeneic Hematopoietic Cell Transplantation. Clin Pharmacol Ther. 2023; 115(1):116-125. PMC: 7615782. DOI: 10.1002/cpt.3078. View

20.

van der Stoep M, Bertaina A, Moes D, Algeri M, Bredius R, Smiers F . Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study. Transplant Cell Ther. 2021; 28(2):99.e1-99.e7. DOI: 10.1016/j.jtct.2021.09.018. View